Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan

This study has been terminated.
(Lack of efficacy)
Information provided by (Responsible Party):
Drugs for Neglected Diseases Identifier:
First received: November 4, 2013
Last updated: October 29, 2015
Last verified: July 2014

This study is designed to determine the efficacy of Fexinidazole as an oral treatment in Visceral Leishmanisasis sudanese adults patients.

The results of this proof of concept study will allow to make a decision on whether to proceed with clinical development of Fexinidazole for visceral leishmaniasis.

Condition Intervention Phase
Visceral Leishmaniasis
Drug: Fexinidazole
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Proof of Concept Trial to Determine Efficacy of Fexinidazole in Visceral Leishmaniasis Patients in Sudan

Resource links provided by NLM:

Further study details as provided by Drugs for Neglected Diseases:

Primary Outcome Measures:
  • Initial cure [ Time Frame: Day 28 ]
    Proportion of patients with an abscence of parasites in tissue aspirate and no rescue treatment administered up to and including day 28

Secondary Outcome Measures:
  • Final cure [ Time Frame: Day 210 ]
    Proportion of patients initially cured at day 28 (or day 56 for slow responders) with no further signs or symptoms of visceral leishmaniasis and no requirement for rescue medication during follow-up phase up to and including the day 210

Other Outcome Measures:
  • Safety endpoint [ Time Frame: From first dose of trial medication to day 56 for non serious AEs and to day 210 for SAEs ]
    Proportion of patients with SAE and/or AEs leading to treatment discontinuation

  • Safety endpoint [ Time Frame: From first dose of trial medication to day 56 ]
    Proportion of patients experiencing at least one non-serious treatment emergent AE

  • Pharmacokinetic assessment [ Time Frame: From day 1 to day 12 ]
    Whole blood concentration of Fexinidazole and metabolites (sulfone and sulfoxide) in an intensive cohort of 10 patients (18 sampling time points) and in a regular cohort for all other patients (6 sampling time points)

  • Pharmacodynamic assessment [ Time Frame: Screening, D1, D3, D5, D8, D11, D14, D28, D56, D210 ]
    Parasite load in blood and bone marrow (if remainder of bone marrow aspirate sample) to follow parasite clearance rate

Enrollment: 14
Study Start Date: November 2013
Study Completion Date: September 2015
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fexinidazole

600mg tablets

3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days

Drug: Fexinidazole

600 mg tablets given orally, after the main daily meal

  • at the daily dose of 1800 mg (3 tablets) once a day for 4 days
  • continued by 1200mg (2 tablets)once a day for 6 days

Detailed Description:

Visceral Leishmaniasis (VL) is a neglected disease and it is fatal if left untreated.

Until recently the first line treatment in East Africa was 30 days of Sodium Stibogluconate which can be cardiotoxic. Since 2010 WHO recommended Sodium Stibogluconate and Paromomycin for 17 days which is a shorter treatment but there remains the toxicity associated with these drugs. The second line treatment is Ambisome given as 6-10 intravenous infusions, whilst this has a better safety profile than other VL regimens it is expensive.

So there is an urgent need for short course oral treatment for VL particularly in the East African region.

Fexinidazole is a 2 substituted 5-nitroimidazole formulated for oral administration. Fexinidazole through its metabolites has demonstrated potent activity againts L. donovani intracellular amastigotes in vitro and in vivo in a visceral leishmaniasis mouse model.

The dose selected for this study (1800 mg/1200 mg for 4/6 days) has been based on the dose selected for a phase II trial on Human African Trypasonomiasis. It is albeit well tolerated and is one dose level below the maximum tolerated dose level established in phase I.

The trial is designed and will be analysed according to a sequential method known as the triangular test, using day 28 data. This sequential design allows for repeated interim analysis (every 10 patients). The null hypothesis is that the proportion cured is less than or equal to 75%. The primary endpoint is initial cure at day 28. The primary population for interim analyses and interim decision making will be the per protocol population.In the final analysis of cumulative patient data, Intention to Treat and Per Protocol Population analyses will be conducted.

The conventional 6 months (day 210) follow up outcome is still an important secondary endpointfor the final decision on whether to proceed with clinical development of Fexinidazole for VL.


Ages Eligible for Study:   15 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with clinical signs and symptoms of primary VL (fever for at least 2 weeks, splenomegaly) and diagnosis confirmed by visualization of parasites in tissue samples (lymph node, bone marrow) on microscopy.
  • Patients aged between 15 and 60 years (inclusive) who are able to comply with the protocol.
  • Patients for whom written informed consent has been signed by the patients themselves (if aged 18 years and over) or by parents(s) or legal guardian for patients under 18 years of age together with the patients assent.
  • HIV negative status

Exclusion Criteria:

  • Patients who have previously been diagnosed with VL and received anti-leishmanial treatment (ie relapse)
  • Patients with BMI <16 kg/m2
  • Patients with contra-indication (known hypersensitivity) to other imidazoles (e.g. ketaconazole)
  • Patients suffering from a concomitant severe underlying disease (cardiac, renal, hepatic) including hepatitis B, para kala-azar dermal leishmaniasis and tuberculosis
  • Patient with clinically significant ECG findings or QTcF≥ 450 msec in 2 successive ECGs
  • Major surgical intervention 4 weeks prior to enrollment.
  • Patients who are pregnant or lactating.
  • Female patients of child bearing age who do not agree to use an acceptable method of contraception
  • Patients with haemoglobin < 5g/dl.
  • Patients with platelets < 40,000/mm³.
  • Patients with liver function (ALT and AST) tests of more than 2 times the upper limit of the normal range.
  • Patients with serum creatinine above the normal range for age and gender.
  • Patients with serum potassium (K+) above the normal range
  • Patients with Bilirubin more than 1.5 times the upper limit of the normal range
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01980199

Doka Hospital
Doka, Gedaref, Sudan
Sponsors and Collaborators
Drugs for Neglected Diseases
Principal Investigator: Ahmed M Musa, MD PhD Director, Institute of Endemic Diseases, University of Khartoum Associate Professor, Head, Department of Clinical Pathology & Immunology
Principal Investigator: E. AG Khalil, Prof. MD Institute of Endemic Diseases (IED), University of Khartoum
  More Information

Responsible Party: Drugs for Neglected Diseases Identifier: NCT01980199     History of Changes
Other Study ID Numbers: FEXI VL 001
Study First Received: November 4, 2013
Last Updated: October 29, 2015

Keywords provided by Drugs for Neglected Diseases:
visceral leishmaniasis
proof of concept

Additional relevant MeSH terms:
Leishmaniasis, Visceral
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases processed this record on April 28, 2017